Global Bipolar Disorder Drugs

Bipolar Disorder Drugs Comprehensive Study by Type (Mood stabilizers, Antipsychotics, Antidepressant drugs, Other drugs), Application (Hospital, Lab, Others), Treatment (Psychotherapy, Medications, Self-management strategies, Complementary health approaches), Disorder type (Bipolar I, Bipolar II, Cyclothymic Disorder or Cyclothymia) Players and Region - Global Market Outlook to 2030

Bipolar Disorder Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 2.72%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Bipolar Disorder Drugs
Bipolar Disorder also called maniac depression results in extreme mood swings. Having this disorder has difficulty in managing everyday tasks. The symptoms include mania, hypomania and depression. In bipolar 1, the person experiences hypomanic or depressive episodes. Whereas, in bipolar 2, the person experiences major depression that lasts at least 2 weeks. According to natural institute of mental health, each year 5.7 million adults are affected by this disorder in United States.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR2.72%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Bipolar Disorder Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Glaxo SmithKline (United Kingdom), Pfizer (United States), Janssen Pharmaceuticals (Belgium), Eli Lilly (United States), Allergan (Ireland), Novartis (Switzerland), AbbVie (United States), Otsuka (Japan), AstraZeneca (United Kingdom) and Abbott Laboratories Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Bristol-Myers Squibb Company (United States), AstraZeneca PLC (United Kingdom), Cephalon Inc. (United States) and Eli Lilly and Company (United States).

Segmentation Overview
AMA Research has segmented the market of Global Bipolar Disorder Drugs market by Type (Mood stabilizers, Antipsychotics, Antidepressant drugs and Other drugs), Application (Hospital, Lab and Others) and Region.



On the basis of geography, the market of Bipolar Disorder Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Psychotherapy will boost the Bipolar Disorder Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disorder type, the sub-segment i.e. Bipolar I will boost the Bipolar Disorder Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Government Initiatives for Increasing Public Awareness about the Bipolar Disorder and Advancements in Therapies of Bipolar Disorder

Market Growth Drivers:
Increase in Prevalence of Bipolar Disorder and Need to Reduce the Burden of Disease from Bipolar Disorder

Challenges:
Lack of Awareness about the Symptoms of Bipolar Disorder

Restraints:
High Costs Associated with the Treatment and Stringent Government Regulations Available

Opportunities:
Rising Awareness of Bipolar Disorder Effects and Increasing Demand of Anti-Depressants in Developed as Well as Developing Countries

Market Leaders and their expansionary development strategies
In March 2024, The Bipolar Disorder (Manic Depression) drugs in development market research report provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
In April 2024, The U.S. FDA approved Vanda Pharmaceuticals' (VNDA.O), opens new tab drug to treat manic and mixed episodes associated with a type of bipolar disorder, the company said on Tuesday, marking the second approval for the treatment.


Key Target Audience
Manufacturers, Raw Material Suppliers, Distributors and Traders, Research Organisations, Government Agencies and Organisations

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Mood stabilizers
  • Antipsychotics
  • Antidepressant drugs
  • Other drugs
By Application
  • Hospital
  • Lab
  • Others
By Treatment
  • Psychotherapy
  • Medications
  • Self-management strategies
  • Complementary health approaches

By Disorder type
  • Bipolar I
  • Bipolar II
  • Cyclothymic Disorder or Cyclothymia

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Prevalence of Bipolar Disorder
      • 3.2.2. Need to Reduce the Burden of Disease from Bipolar Disorder
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness about the Symptoms of Bipolar Disorder
    • 3.4. Market Trends
      • 3.4.1. Government Initiatives for Increasing Public Awareness about the Bipolar Disorder
      • 3.4.2. Advancements in Therapies of Bipolar Disorder
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bipolar Disorder Drugs, by Type, Application, Treatment, Disorder type and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Bipolar Disorder Drugs (Value)
      • 5.2.1. Global Bipolar Disorder Drugs by: Type (Value)
        • 5.2.1.1. Mood stabilizers
        • 5.2.1.2. Antipsychotics
        • 5.2.1.3. Antidepressant drugs
        • 5.2.1.4. Other drugs
      • 5.2.2. Global Bipolar Disorder Drugs by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Lab
        • 5.2.2.3. Others
      • 5.2.3. Global Bipolar Disorder Drugs by: Treatment (Value)
        • 5.2.3.1. Psychotherapy
        • 5.2.3.2. Medications
        • 5.2.3.3. Self-management strategies
        • 5.2.3.4. Complementary health approaches
      • 5.2.4. Global Bipolar Disorder Drugs by: Disorder type (Value)
        • 5.2.4.1. Bipolar I
        • 5.2.4.2. Bipolar II
        • 5.2.4.3. Cyclothymic Disorder or Cyclothymia
      • 5.2.5. Global Bipolar Disorder Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Bipolar Disorder Drugs (Price)
      • 5.3.1. Global Bipolar Disorder Drugs by: Type (Price)
  • 6. Bipolar Disorder Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Glaxo SmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Janssen Pharmaceuticals (Belgium)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Allergan (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AbbVie (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Otsuka (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Abbott Laboratories Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Bipolar Disorder Drugs Sale, by Type, Application, Treatment, Disorder type and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Bipolar Disorder Drugs (Value)
      • 7.2.1. Global Bipolar Disorder Drugs by: Type (Value)
        • 7.2.1.1. Mood stabilizers
        • 7.2.1.2. Antipsychotics
        • 7.2.1.3. Antidepressant drugs
        • 7.2.1.4. Other drugs
      • 7.2.2. Global Bipolar Disorder Drugs by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Lab
        • 7.2.2.3. Others
      • 7.2.3. Global Bipolar Disorder Drugs by: Treatment (Value)
        • 7.2.3.1. Psychotherapy
        • 7.2.3.2. Medications
        • 7.2.3.3. Self-management strategies
        • 7.2.3.4. Complementary health approaches
      • 7.2.4. Global Bipolar Disorder Drugs by: Disorder type (Value)
        • 7.2.4.1. Bipolar I
        • 7.2.4.2. Bipolar II
        • 7.2.4.3. Cyclothymic Disorder or Cyclothymia
      • 7.2.5. Global Bipolar Disorder Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Bipolar Disorder Drugs (Price)
      • 7.3.1. Global Bipolar Disorder Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bipolar Disorder Drugs: by Type(USD Million)
  • Table 2. Bipolar Disorder Drugs Mood stabilizers , by Region USD Million (2018-2023)
  • Table 3. Bipolar Disorder Drugs Antipsychotics , by Region USD Million (2018-2023)
  • Table 4. Bipolar Disorder Drugs Antidepressant drugs , by Region USD Million (2018-2023)
  • Table 5. Bipolar Disorder Drugs Other drugs , by Region USD Million (2018-2023)
  • Table 6. Bipolar Disorder Drugs: by Application(USD Million)
  • Table 7. Bipolar Disorder Drugs Hospital , by Region USD Million (2018-2023)
  • Table 8. Bipolar Disorder Drugs Lab , by Region USD Million (2018-2023)
  • Table 9. Bipolar Disorder Drugs Others , by Region USD Million (2018-2023)
  • Table 10. Bipolar Disorder Drugs: by Treatment(USD Million)
  • Table 11. Bipolar Disorder Drugs Psychotherapy , by Region USD Million (2018-2023)
  • Table 12. Bipolar Disorder Drugs Medications , by Region USD Million (2018-2023)
  • Table 13. Bipolar Disorder Drugs Self-management strategies , by Region USD Million (2018-2023)
  • Table 14. Bipolar Disorder Drugs Complementary health approaches , by Region USD Million (2018-2023)
  • Table 15. Bipolar Disorder Drugs: by Disorder type(USD Million)
  • Table 16. Bipolar Disorder Drugs Bipolar I , by Region USD Million (2018-2023)
  • Table 17. Bipolar Disorder Drugs Bipolar II , by Region USD Million (2018-2023)
  • Table 18. Bipolar Disorder Drugs Cyclothymic Disorder or Cyclothymia , by Region USD Million (2018-2023)
  • Table 19. South America Bipolar Disorder Drugs, by Country USD Million (2018-2023)
  • Table 20. South America Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 21. South America Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 22. South America Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 23. South America Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 24. Brazil Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 25. Brazil Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 26. Brazil Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 27. Brazil Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 28. Argentina Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 29. Argentina Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 30. Argentina Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 31. Argentina Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 32. Rest of South America Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 33. Rest of South America Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 34. Rest of South America Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 35. Rest of South America Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 36. Asia Pacific Bipolar Disorder Drugs, by Country USD Million (2018-2023)
  • Table 37. Asia Pacific Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 38. Asia Pacific Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 39. Asia Pacific Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 40. Asia Pacific Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 41. China Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 42. China Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 43. China Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 44. China Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 45. Japan Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 46. Japan Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 47. Japan Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 48. Japan Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 49. India Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 50. India Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 51. India Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 52. India Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 53. South Korea Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 54. South Korea Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 55. South Korea Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 56. South Korea Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 57. Taiwan Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 58. Taiwan Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 59. Taiwan Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 60. Taiwan Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 61. Australia Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 62. Australia Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 63. Australia Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 64. Australia Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 69. Europe Bipolar Disorder Drugs, by Country USD Million (2018-2023)
  • Table 70. Europe Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 71. Europe Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 72. Europe Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 73. Europe Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 74. Germany Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 75. Germany Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 76. Germany Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 77. Germany Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 78. France Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 79. France Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 80. France Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 81. France Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 82. Italy Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 83. Italy Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 84. Italy Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 85. Italy Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 86. United Kingdom Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 87. United Kingdom Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 88. United Kingdom Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 89. United Kingdom Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 90. Netherlands Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 91. Netherlands Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 92. Netherlands Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 93. Netherlands Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 94. Rest of Europe Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 95. Rest of Europe Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 96. Rest of Europe Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 97. Rest of Europe Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 98. MEA Bipolar Disorder Drugs, by Country USD Million (2018-2023)
  • Table 99. MEA Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 100. MEA Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 101. MEA Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 102. MEA Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 103. Middle East Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 104. Middle East Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 105. Middle East Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 106. Middle East Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 107. Africa Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 108. Africa Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 109. Africa Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 110. Africa Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 111. North America Bipolar Disorder Drugs, by Country USD Million (2018-2023)
  • Table 112. North America Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 113. North America Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 114. North America Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 115. North America Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 116. United States Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 117. United States Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 118. United States Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 119. United States Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 120. Canada Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 121. Canada Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 122. Canada Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 123. Canada Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 124. Mexico Bipolar Disorder Drugs, by Type USD Million (2018-2023)
  • Table 125. Mexico Bipolar Disorder Drugs, by Application USD Million (2018-2023)
  • Table 126. Mexico Bipolar Disorder Drugs, by Treatment USD Million (2018-2023)
  • Table 127. Mexico Bipolar Disorder Drugs, by Disorder type USD Million (2018-2023)
  • Table 128. Bipolar Disorder Drugs: by Type(USD/Units)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Bipolar Disorder Drugs: by Type(USD Million)
  • Table 140. Bipolar Disorder Drugs Mood stabilizers , by Region USD Million (2025-2030)
  • Table 141. Bipolar Disorder Drugs Antipsychotics , by Region USD Million (2025-2030)
  • Table 142. Bipolar Disorder Drugs Antidepressant drugs , by Region USD Million (2025-2030)
  • Table 143. Bipolar Disorder Drugs Other drugs , by Region USD Million (2025-2030)
  • Table 144. Bipolar Disorder Drugs: by Application(USD Million)
  • Table 145. Bipolar Disorder Drugs Hospital , by Region USD Million (2025-2030)
  • Table 146. Bipolar Disorder Drugs Lab , by Region USD Million (2025-2030)
  • Table 147. Bipolar Disorder Drugs Others , by Region USD Million (2025-2030)
  • Table 148. Bipolar Disorder Drugs: by Treatment(USD Million)
  • Table 149. Bipolar Disorder Drugs Psychotherapy , by Region USD Million (2025-2030)
  • Table 150. Bipolar Disorder Drugs Medications , by Region USD Million (2025-2030)
  • Table 151. Bipolar Disorder Drugs Self-management strategies , by Region USD Million (2025-2030)
  • Table 152. Bipolar Disorder Drugs Complementary health approaches , by Region USD Million (2025-2030)
  • Table 153. Bipolar Disorder Drugs: by Disorder type(USD Million)
  • Table 154. Bipolar Disorder Drugs Bipolar I , by Region USD Million (2025-2030)
  • Table 155. Bipolar Disorder Drugs Bipolar II , by Region USD Million (2025-2030)
  • Table 156. Bipolar Disorder Drugs Cyclothymic Disorder or Cyclothymia , by Region USD Million (2025-2030)
  • Table 157. South America Bipolar Disorder Drugs, by Country USD Million (2025-2030)
  • Table 158. South America Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 159. South America Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 160. South America Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 161. South America Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 162. Brazil Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 163. Brazil Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 164. Brazil Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 165. Brazil Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 166. Argentina Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 167. Argentina Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 168. Argentina Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 169. Argentina Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 170. Rest of South America Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 171. Rest of South America Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 172. Rest of South America Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 173. Rest of South America Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 174. Asia Pacific Bipolar Disorder Drugs, by Country USD Million (2025-2030)
  • Table 175. Asia Pacific Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 176. Asia Pacific Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 177. Asia Pacific Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 178. Asia Pacific Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 179. China Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 180. China Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 181. China Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 182. China Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 183. Japan Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 184. Japan Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 185. Japan Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 186. Japan Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 187. India Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 188. India Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 189. India Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 190. India Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 191. South Korea Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 192. South Korea Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 193. South Korea Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 194. South Korea Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 195. Taiwan Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 196. Taiwan Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 197. Taiwan Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 198. Taiwan Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 199. Australia Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 200. Australia Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 201. Australia Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 202. Australia Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 206. Rest of Asia-Pacific Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 207. Europe Bipolar Disorder Drugs, by Country USD Million (2025-2030)
  • Table 208. Europe Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 209. Europe Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 210. Europe Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 211. Europe Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 212. Germany Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 213. Germany Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 214. Germany Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 215. Germany Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 216. France Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 217. France Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 218. France Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 219. France Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 220. Italy Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 221. Italy Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 222. Italy Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 223. Italy Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 224. United Kingdom Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 225. United Kingdom Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 226. United Kingdom Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 227. United Kingdom Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 228. Netherlands Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 229. Netherlands Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 230. Netherlands Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 231. Netherlands Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 232. Rest of Europe Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 233. Rest of Europe Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 234. Rest of Europe Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 235. Rest of Europe Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 236. MEA Bipolar Disorder Drugs, by Country USD Million (2025-2030)
  • Table 237. MEA Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 238. MEA Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 239. MEA Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 240. MEA Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 241. Middle East Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 242. Middle East Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 243. Middle East Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 244. Middle East Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 245. Africa Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 246. Africa Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 247. Africa Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 248. Africa Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 249. North America Bipolar Disorder Drugs, by Country USD Million (2025-2030)
  • Table 250. North America Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 251. North America Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 252. North America Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 253. North America Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 254. United States Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 255. United States Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 256. United States Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 257. United States Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 258. Canada Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 259. Canada Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 260. Canada Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 261. Canada Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 262. Mexico Bipolar Disorder Drugs, by Type USD Million (2025-2030)
  • Table 263. Mexico Bipolar Disorder Drugs, by Application USD Million (2025-2030)
  • Table 264. Mexico Bipolar Disorder Drugs, by Treatment USD Million (2025-2030)
  • Table 265. Mexico Bipolar Disorder Drugs, by Disorder type USD Million (2025-2030)
  • Table 266. Bipolar Disorder Drugs: by Type(USD/Units)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bipolar Disorder Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Bipolar Disorder Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Bipolar Disorder Drugs: by Treatment USD Million (2018-2023)
  • Figure 7. Global Bipolar Disorder Drugs: by Disorder type USD Million (2018-2023)
  • Figure 8. South America Bipolar Disorder Drugs Share (%), by Country
  • Figure 9. Asia Pacific Bipolar Disorder Drugs Share (%), by Country
  • Figure 10. Europe Bipolar Disorder Drugs Share (%), by Country
  • Figure 11. MEA Bipolar Disorder Drugs Share (%), by Country
  • Figure 12. North America Bipolar Disorder Drugs Share (%), by Country
  • Figure 13. Global Bipolar Disorder Drugs: by Type USD/Units (2018-2023)
  • Figure 14. Global Bipolar Disorder Drugs share by Players 2023 (%)
  • Figure 15. Global Bipolar Disorder Drugs share by Players (Top 3) 2023(%)
  • Figure 16. Global Bipolar Disorder Drugs share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Glaxo SmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. Glaxo SmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 20. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer (United States) Revenue: by Geography 2023
  • Figure 22. Janssen Pharmaceuticals (Belgium) Revenue, Net Income and Gross profit
  • Figure 23. Janssen Pharmaceuticals (Belgium) Revenue: by Geography 2023
  • Figure 24. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 25. Eli Lilly (United States) Revenue: by Geography 2023
  • Figure 26. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 27. Allergan (Ireland) Revenue: by Geography 2023
  • Figure 28. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 30. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 31. AbbVie (United States) Revenue: by Geography 2023
  • Figure 32. Otsuka (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Otsuka (Japan) Revenue: by Geography 2023
  • Figure 34. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 36. Abbott Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Abbott Laboratories Inc. (United States) Revenue: by Geography 2023
  • Figure 38. Global Bipolar Disorder Drugs: by Type USD Million (2025-2030)
  • Figure 39. Global Bipolar Disorder Drugs: by Application USD Million (2025-2030)
  • Figure 40. Global Bipolar Disorder Drugs: by Treatment USD Million (2025-2030)
  • Figure 41. Global Bipolar Disorder Drugs: by Disorder type USD Million (2025-2030)
  • Figure 42. South America Bipolar Disorder Drugs Share (%), by Country
  • Figure 43. Asia Pacific Bipolar Disorder Drugs Share (%), by Country
  • Figure 44. Europe Bipolar Disorder Drugs Share (%), by Country
  • Figure 45. MEA Bipolar Disorder Drugs Share (%), by Country
  • Figure 46. North America Bipolar Disorder Drugs Share (%), by Country
  • Figure 47. Global Bipolar Disorder Drugs: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Glaxo SmithKline (United Kingdom)
  • Pfizer (United States)
  • Janssen Pharmaceuticals (Belgium)
  • Eli Lilly (United States)
  • Allergan (Ireland)
  • Novartis (Switzerland)
  • AbbVie (United States)
  • Otsuka (Japan)
  • AstraZeneca (United Kingdom)
  • Abbott Laboratories Inc. (United States)
Additional players considered in the study are as follows:
Bristol-Myers Squibb Company (United States) , AstraZeneca PLC (United Kingdom) , Cephalon Inc. (United States) , Eli Lilly and Company (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 211 Pages 61 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bipolar Disorder Drugs Quantitative research analysis
Global Bipolar Disorder Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Glaxo SmithKline (United Kingdom), Pfizer (United States), Janssen Pharmaceuticals (Belgium), Eli Lilly (United States), Allergan (Ireland), Novartis (Switzerland), AbbVie (United States), Otsuka (Japan), AstraZeneca (United Kingdom) and Abbott Laboratories Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Government Initiatives for Increasing Public Awareness about the Bipolar Disorder " is seen as one of major influencing trends for Bipolar Disorder Drugs Market during projected period 2023-2030.
The Bipolar Disorder Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Bipolar Disorder Drugs Report?

Have a Query? Click Here

Other Related Reports

Ethical Pharmaceuticals Comprehensive Study by Application (Hospitals and Clinics, Pharmaceutical Company, Others), Formulations (Enteral (Tablets, Capsules), Parenteral (Liquid, Lyophilized), Topica...
$ 3750
Novel Drug Delivery Systems Comprehensive Study by Type (Liposomes, PEGylated Proteins & Polypeptides, Polymer Nanoparticle, Protein Drug Conjugates, Others), Application (Hospitals & Clinic, Cancer ...
$ 3750
Skin Ulcer Wound Care Products Comprehensive Study by Type (Pressure Ulcer, Diabetic Ulcer, Venous Ulcer, Arterial Ulcer), Application (Hospitals, Clinics, Others) Players and Region - Global Market ...
$ 3500
IV Fluids Comprehensive Study by Type (Colloids, Crystalloids, Blood and blood products, Oxygen-carrying solutions), Composition (Normal Saline {0.9% Normal Saline (0.9% NaCl}, Hypertonic saline {3, ...
$ 3650
Nelarabine Comprehensive Study by Application (Pregnancy, Nursing Mothers, Pediatric Use, Geriatric Use, Renal Impairment, Hepatic Impairment, Others), Distribution Channel (Online Channels, Offline ...
$ 3650
Degarelix Comprehensive Study by Type (120 mg per vial, 80 mg per vial), Application (Hospital, Drug store), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2028
$ 3500